Call Options

7 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$33.68 - $44.74 $458,048 - $608,464
13,600 New
13,600 $530,000
Q1 2024

May 07, 2024

BUY
$24.92 - $30.02 $82,236 - $99,066
3,300 Added 46.48%
10,400 $261,000
Q4 2023

Feb 14, 2024

SELL
$27.14 - $34.93 $784,346 - $1.01 Million
-28,900 Reduced 80.28%
7,100 $209,000
Q3 2023

Nov 14, 2023

BUY
$24.63 - $32.85 $886,680 - $1.18 Million
36,000 New
36,000 $1.14 Million
Q1 2022

May 16, 2022

BUY
$15.5 - $23.93 $6,200 - $9,572
400 Added 2.86%
14,400 $317,000
Q4 2021

Feb 14, 2022

SELL
$13.05 - $19.35 $130,500 - $193,500
-10,000 Reduced 41.67%
14,000 $223,000
Q3 2021

Nov 15, 2021

BUY
$13.95 - $20.18 $334,800 - $484,320
24,000 New
24,000 $478,000

Others Institutions Holding MIRM

About Mirum Pharmaceuticals, Inc.


  • Ticker MIRM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,751,700
  • Market Cap $1.56B
  • Description
  • Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...
More about MIRM
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.